2 FTSE 100-beaters that could fund your retirement

These two stocks could continue their outperformance of the FTSE 100 (INDEXFTSE:UKX).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the FTSE 100 having risen by 3% in the last six months, it has generally been a prosperous period for investors. Certainly, there has been relatively high volatility, but capital growth has nevertheless been in line with long-term expectations. Over the same time period, two stocks have significantly outperformed the wider index. Looking ahead, more growth could be on the horizon.

Sound performance

Releasing an AGM statement on Friday was connected healthcare software and services specialist EMIS (LSE: EMIS). The company’s trading for the year to date has been in line with its expectations. This has benefited from its strong revenue visibility, growing market share, as well as solid order books and pipelines across all of its key sectors.

The structural reorganisation of the business is now mostly complete. This has brought together Primary Care, Secondary Care and CCMH, which could provide greater efficiencies and higher growth prospects in the long run. The costs of the restructuring will be expensed in the first half of the year, which should provide an uplift to the company’s performance later in the year.

Clearly, the change in the company’s CEO could bring a degree of risk. However, EMIS seems to have a sound strategy through which to deliver improving growth in future years. For example, it is expected to report a rise in its bottom line of 4% in the next financial year.

While in the current year the company’s earnings growth rate is expected to move into the red, the growth potential from its restructuring means it should deliver FTSE 100-beating performance in future. Investor sentiment seems high following its 12% rise in the last six months, which could continue over the medium term.

Volatile growth

Also offering upside potential is trading and risk management software provider Brady (LSE: BRY). Its share price has risen by 3x the amount of the FTSE 100 in the last six months, with more growth set to be recorded in future.

Certainly, Brady has a rather chequered track record of financial performance. In the last five years its bottom line has fallen by around 40%, yet it has been able to deliver a couple of standout years where earnings have doubled versus their prior year on a per share basis. This trend looks set to continue over the next two years, with the company expected to report a fall in its bottom line of 46% this year, followed by growth of 143% next year. This could stimulate investor sentiment through 2017 and 2018.

With Brady trading on a price-to-earnings growth (PEG) ratio of 0.2, it appears to have a sufficiently wide margin of safety to merit investment at the present time. Investors seem to have priced in the potential for highly volatile growth, meaning now could be an optimum time to buy the shares for the long run.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has recommended Emis Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing For Beginners

The Barclays share price keeps surging! Was I wrong to sell the stock?

Jon Smith explains why the Barclays share price is still rising, even though he feels that further gains could be…

Read more »

Investing Articles

1 stock set to gatecrash the FTSE 100 in 2025!

Our writer considers a quality stock that's poised to join the FTSE 100 next year. Could there also be a…

Read more »

Businesswoman calculating finances in an office
Investing Articles

As earnings growth boosts the Imperial Brands share price, is it a top FTSE 100 dividend choice?

The Imperial Brands share price has come storming back as investors piled in for the big dividends. What's next, after…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
US Stock

Warren Buffett just bought and sold these stocks. Here’s why I don’t agree

Jon Smith takes a look at the recent regulatory filing for Berkshire Hathaway and Warren Buffett and comments on recent…

Read more »

US Stock

My favourite US growth stock’s up 33% this year. I think it’s just getting started

Edward Sheldon's taken a large position in this well-known S&P 500 growth stock. And so far, it’s working very well…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

The Diploma share price falls 7% as revenues and profits keep growing. Time to buy?

As Diploma continues its impressive growth, its share price is faltering. Stephen Wright takes a closer look at one of…

Read more »

Growth Shares

Directors at this FTSE 100 company just bought over £2m worth of shares

Shares in this FTSE 100 pharma company have plummeted in recent months. And company insiders are betting on a potential…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Down 24%! As the Glencore share price falls like snow, is it finally time to let it go?

Harvey Jones thought the Glencore share price was in bargain territory when he bought the FTSE 100 commodity giant last…

Read more »